









市场行情
/
股票
/
nasdaq-plrx
/

Pliant Therapeutics Inc

PLRX

1.230USD

+0.020+1.65%

收盘 12/19, 16:00（美东）报价延迟15分钟

75.58M总市值

亏损市盈率 TTM



Pliant Therapeutics Inc

1.230

+0.020+1.65%

概览公司财务分析

概览

公司

财务

分析

关于 Pliant Therapeutics Inc 公司

Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.

Pliant Therapeutics Inc简介



公司代码PLRX

公司名称Pliant Therapeutics Inc

上市日期Jun 03, 2020

CEOCoulie (Bernard J)

员工数量171

证券类型Ordinary Share

年结日Jun 03

公司地址331 Oyster Point Boulevard

城市SOUTH SAN FRANCISCO

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编94080

电话16504816770

网址https://pliantrx.com/

公司代码PLRX

上市日期Jun 03, 2020

CEOCoulie (Bernard J)

Pliant Therapeutics Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Bernard J. Coulie, M.D., Ph.D.

President, Chief Executive Officer, Director

705.63K

-8.97%

Dr. Hoyoung Huh, M.D., Ph.D.

Non-Executive Chairman of the Board, Lead Independent Director

99.76K

Dr. Suzanne Louise (Sue) Bruhn, Ph.D.

Independent Director

35.08K

Dr. John T. Curnutte, M.D., Ph.D.

Independent Director

29.28K

Ms. Lily Cheung

Chief Human Resources Officer

7.22K

-68.53%

Mr. Christopher Keenan

Vice President - Investor Relations and Corporate Communications

Dr. Eric Lefebvre, M.D.

Chief Medical Officer

Mr. David E. I. Pyott, CBE

Independent Director

Dr. Delphine Imbert, Ph.D.

Chief Technical Officer

Mr. Darren S. Cline

Independent Director

名称

名称/职务

职务

持股

持股变动

Dr. Bernard J. Coulie, M.D., Ph.D.

President, Chief Executive Officer, Director

705.63K

-8.97%

Dr. Hoyoung Huh, M.D., Ph.D.

Non-Executive Chairman of the Board, Lead Independent Director

99.76K

Dr. Suzanne Louise (Sue) Bruhn, Ph.D.

Independent Director

35.08K

Dr. John T. Curnutte, M.D., Ph.D.

Independent Director

29.28K

Ms. Lily Cheung

Chief Human Resources Officer

7.22K

-68.53%

Mr. Christopher Keenan

Vice President - Investor Relations and Corporate Communications

收入明细

FY2024

由于公司未披露，未能获取相关数据

地区USD

名称

营收

占比

United States

0.00

0.00%

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月16日周日

持股股东

股东类型

持股股东

占比

Tang Capital Management, LLC

9.77%

Woodline Partners LP

7.33%

Point72 Asset Management, L.P.

7.06%

Morgan Stanley & Co. LLC

5.69%

Blue Owl Capital Holdings LP

4.83%

其他

65.32%

持股股东

占比

Tang Capital Management, LLC

9.77%

Woodline Partners LP

7.33%

Point72 Asset Management, L.P.

7.06%

Morgan Stanley & Co. LLC

5.69%

Blue Owl Capital Holdings LP

4.83%

其他

65.32%

股东类型

持股股东

占比

Hedge Fund

37.34%

Investment Advisor

20.88%

Investment Advisor/Hedge Fund

12.64%

Research Firm

12.08%

Individual Investor

2.52%

Family Office

0.87%

Venture Capital

0.76%

Private Equity

0.04%

Bank and Trust

0.02%

其他

12.86%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

356

52.49M

85.42%

-37.39M

2025Q2

374

62.63M

102.02%

-15.09M

2025Q1

390

63.45M

103.37%

-12.99M

2024Q4

392

71.13M

116.20%

-8.66M

2024Q3

388

69.61M

114.50%

-7.63M

2024Q2

375

69.93M

115.87%

-7.66M

2024Q1

371

73.36M

121.74%

-3.24M

2023Q4

362

70.03M

116.83%

-95.89K

2023Q3

356

64.13M

107.25%

-2.06M

2023Q2

347

62.06M

104.99%

-496.00K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Tang Capital Management, LLC

6.00M

9.77%

Jun 30, 2025

Woodline Partners LP

2.35M

3.83%

-165.56K

-6.59%

Jun 30, 2025

Morgan Stanley & Co. LLC

1.99M

3.25%

+965.53K

+93.93%

Jun 30, 2025

Blue Owl Capital Holdings LP

2.97M

4.84%

Jun 30, 2025

The Vanguard Group, Inc.

3.00M

4.89%

-322.88K

-9.71%

Jun 30, 2025

Acadian Asset Management LLC

1.63M

2.66%

+409.97K

+33.59%

Jun 30, 2025

Citadel Advisors LLC

2.36M

3.84%

+2.36M

+3624360.00%

Jun 30, 2025

J.P. Morgan Securities LLC

1.95M

3.18%

+1.52M

+352.69%

Jun 30, 2025

Two Sigma Investments, LP

745.40K

1.21%

+127.91K

+20.72%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

iShares Micro-Cap ETF

0.02%

Invesco RAFI US 1500 Small-Mid ETF

0.01%

ProShares Ultra Nasdaq Biotechnology

0.01%

iShares Biotechnology ETF

0.01%

Invesco Nasdaq Biotechnology ETF

0.01%

DFA Dimensional US Core Equity Market ETF

Schwab U.S. Small-Cap ETF

Global X Russell 2000 Covered Call ETF

Humankind US Stock ETF

iShares Morningstar Small-Cap Value ETF

iShares Micro-Cap ETF

占比0.02%

Invesco RAFI US 1500 Small-Mid ETF

占比0.01%

ProShares Ultra Nasdaq Biotechnology

占比0.01%

iShares Biotechnology ETF

占比0.01%

Invesco Nasdaq Biotechnology ETF

占比0.01%

DFA Dimensional US Core Equity Market ETF

占比0%

Schwab U.S. Small-Cap ETF

占比0%

Global X Russell 2000 Covered Call ETF

占比0%

Humankind US Stock ETF

占比0%

iShares Morningstar Small-Cap Value ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Pliant Therapeutics Inc的前五大股东是谁？



Pliant Therapeutics Inc 的前五大股东如下：
Tang Capital Management, LLC持有股份：6.00M，占总股份比例：9.77%。
Woodline Partners LP持有股份：2.35M，占总股份比例：3.83%。
Morgan Stanley & Co. LLC持有股份：1.99M，占总股份比例：3.25%。
Blue Owl Capital Holdings LP持有股份：2.97M，占总股份比例：4.84%。
The Vanguard Group, Inc.持有股份：3.00M，占总股份比例：4.89%。